On January 5, the Associated Press reported that Bristol Myers Squibb (announced that the original tumor treatment drug Abraxane (paclitaxel for injection [albumin conjugated], referred to as "albumin paclitaxel") was approved by the State Drug Administration of China (NMPA) and is applicable to the combination of gemcitabine as the first-line treatment of metastatic pancreatic cancer. Abraxane is the original product of albumin paclitaxel, which has been proved by phase 3 clinical studies to significantly improve the survival of patients with pancreatic cancer.